Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EXActDNA-003 / NSABP B-64: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease

NCT06401421 is registered in ClinicalTrials.gov with Exact Sciences Corporation as lead sponsor.

NCT NCT06401421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06401421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EXActDNA-003 / NSABP B-64: Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
Lead sponsor
Exact Sciences Corporation
Phase
Observational
Overall status
Recruiting
Start date
June 7, 2024
Completion date
April 30, 2030
Enrollment
1,800 (estimated)
Sites
58

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer